{"hands_on_practices": [{"introduction": "The interaction between viral oncoproteins and host cell proteins is at the heart of cellular transformation. This practice moves beyond qualitative descriptions to a quantitative model of a canonical event in viral oncogenesis: the degradation of the p53 tumor suppressor protein mediated by the HPV E6 oncoprotein [@problem_id:2516291]. By applying fundamental principles of reaction kinetics to model protein synthesis and degradation, you will derive how the steady-state level of p53 changes in an infected cell, providing a concrete mathematical basis for understanding how viral hijacking impairs a cell's critical defenses against DNA damage.", "problem": "A mammalian cell maintains a pool of tumor protein p53 (p53) that is continuously synthesized and degraded. Consider a single, well-mixed cell in which p53 is synthesized at an approximately constant rate $s$ (zero-order synthesis) and removed by the ubiquitin-proteasome system (UPS) with first-order kinetics characterized by a degradation rate constant $k$. High-risk Human Papillomavirus (HPV) expresses the E6 oncoprotein, which recruits E6-associated protein (E6-AP) to enhance p53 ubiquitination, effectively increasing the first-order degradation rate constant by a multiplicative factor $\\gamma > 1$, while leaving the synthesis rate unchanged.\n\nStarting only from (i) the mass-balance principle that the time rate of change of a species equals its rate of input minus its rate of removal, and (ii) the definition of first-order kinetics and half-life, perform the following:\n\n1. Derive the differential equation for the temporal dynamics of p53 copy number $P(t)$ in the absence of HPV E6. Define the steady state $P_{\\mathrm{ss}}$ and derive it in terms of $s$ and $k$. Then, express the new steady state $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$ when E6 increases the degradation rate constant to $k^{\\prime}=\\gamma k$.\n\n2. Use the definition of half-life for a first-order process to relate $k$ to the baseline p53 half-life $t_{1/2}$. Then compute the numerical value of $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$ for the parameter set $s=9.0$ molecules s$^{-1}$ cell$^{-1}$, $t_{1/2}=30$ minutes, and $\\gamma=4.0$. Round your answer to three significant figures. Express your final answer in molecules per cell.\n\n3. Briefly interpret, in qualitative terms, how the change from $P_{\\mathrm{ss}}$ to $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$ would be expected to influence the propensity for apoptosis under a DNA damage signal if apoptosis initiation increases monotonically with steady-state p53 abundance.\n\nYour final reported quantity must be only the value of $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$ as a single number.", "solution": "The problem requires a three-part analysis. We will address each part in sequence.\n\nPart 1: Derivation of the governing differential equation and steady-state expressions.\n\nThe fundamental principle is the mass-balance equation for the copy number of p53 protein, $P(t)$, within the single cell volume. The time rate of change of $P(t)$ is the difference between its rate of synthesis and its rate of removal:\n$$\n\\frac{dP(t)}{dt} = (\\text{Rate of Synthesis}) - (\\text{Rate of Removal})\n$$\nThe problem states that synthesis is a zero-order process, meaning its rate is a constant, which we denote by $s$. The units are molecules per unit time.\n$$\n\\text{Rate of Synthesis} = s\n$$\nDegradation, in the absence of Human Papillomavirus (HPV), follows first-order kinetics. This means the rate of removal is directly proportional to the current amount of the species, $P(t)$. The constant of proportionality is the degradation rate constant, $k$.\n$$\n\\text{Rate of Removal} = k P(t)\n$$\nCombining these terms gives the differential equation for the temporal dynamics of p53 copy number in an uninfected cell:\n$$\n\\frac{dP(t)}{dt} = s - k P(t)\n$$\nThe steady state is defined as the condition where the concentration, or copy number, no longer changes with time. Mathematically, this corresponds to the state where the time derivative is zero. Let $P_{\\mathrm{ss}}$ be the steady-state copy number.\n$$\n\\frac{d P_{\\mathrm{ss}}}{dt} = 0\n$$\nSubstituting this into the differential equation yields:\n$$\n0 = s - k P_{\\mathrm{ss}}\n$$\nSolving for $P_{\\mathrm{ss}}$ gives the steady-state p53 copy number in terms of the synthesis and degradation rates:\n$$\nP_{\\mathrm{ss}} = \\frac{s}{k}\n$$\nNow, we consider the case where the HPV E6 oncoprotein is present. The problem states that E6 enhances the degradation rate by a multiplicative factor $\\gamma > 1$, while leaving the synthesis rate $s$ unchanged. The new degradation rate constant, $k^{\\prime}$, is therefore:\n$$\nk^{\\prime} = \\gamma k\n$$\nThe governing differential equation is modified accordingly:\n$$\n\\frac{dP(t)}{dt} = s - k^{\\prime} P(t) = s - (\\gamma k) P(t)\n$$\nThe new steady state, which we denote $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$, is found by again setting the time derivative to zero:\n$$\n0 = s - \\gamma k P_{\\mathrm{ss}}^{(\\mathrm{E6})}\n$$\nSolving for the new steady-state copy number gives:\n$$\nP_{\\mathrm{ss}}^{(\\mathrm{E6})} = \\frac{s}{\\gamma k}\n$$\nIt is clear from inspection that $P_{\\mathrm{ss}}^{(\\mathrm{E6})} = \\frac{1}{\\gamma} P_{\\mathrm{ss}}$. Since $\\gamma > 1$, the presence of E6 reduces the steady-state level of p53.\n\nPart 2: Relation of the rate constant to half-life and numerical calculation.\n\nThe half-life, $t_{1/2}$, of a species undergoing a first-order decay process is the time required for its concentration to decrease to half of its initial value. Consider the decay process in the absence of synthesis, described by $\\frac{dP}{dt} = -kP$. The solution to this equation is $P(t) = P_0 \\exp(-kt)$, where $P_0$ is the initial concentration at $t=0$.\nBy definition of half-life, at $t=t_{1/2}$, we have $P(t_{1/2}) = \\frac{1}{2} P_0$.\n$$\n\\frac{1}{2} P_0 = P_0 \\exp(-k t_{1/2})\n$$\nDividing by $P_0$ (which is non-zero) and taking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2}\n$$\n$$\n-\\ln(2) = -k t_{1/2}\n$$\nThis gives the fundamental relationship between the first-order rate constant and half-life:\n$$\nk = \\frac{\\ln(2)}{t_{1/2}}\n$$\nWe can now substitute this expression for $k$ into our derived formula for $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$:\n$$\nP_{\\mathrm{ss}}^{(\\mathrm{E6})} = \\frac{s}{\\gamma k} = \\frac{s}{\\gamma \\left(\\frac{\\ln(2)}{t_{1/2}}\\right)} = \\frac{s t_{1/2}}{\\gamma \\ln(2)}\n$$\nWe are given the following parameter values:\n$s = 9.0$ molecules s$^{-1}$ cell$^{-1}$\n$t_{1/2} = 30$ minutes\n$\\gamma = 4.0$\n\nBefore calculation, we must ensure consistency of units. The synthesis rate $s$ is given in seconds, while the half-life $t_{1/2}$ is in minutes. We convert minutes to seconds:\n$$\nt_{1/2} = 30 \\text{ min} \\times \\frac{60 \\text{ s}}{1 \\text{ min}} = 1800 \\text{ s}\n$$\nNow we substitute the numerical values into the expression for $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$:\n$$\nP_{\\mathrm{ss}}^{(\\mathrm{E6})} = \\frac{(9.0 \\text{ s}^{-1}) (1800 \\text{ s})}{(4.0) \\ln(2)} = \\frac{16200}{4.0 \\ln(2)} = \\frac{4050}{\\ln(2)}\n$$\nUsing the value $\\ln(2) \\approx 0.693147...$, we compute the final numerical result:\n$$\nP_{\\mathrm{ss}}^{(\\mathrm{E6})} \\approx \\frac{4050}{0.693147} \\approx 5842.86 \\text{ molecules/cell}\n$$\nThe problem requires the answer to be rounded to three significant figures.\n$$\nP_{\\mathrm{ss}}^{(\\mathrm{E6})} \\approx 5840 \\text{ molecules/cell}\n$$\nIn scientific notation, this is $5.84 \\times 10^3$ molecules/cell.\n\nPart 3: Qualitative interpretation.\n\nThe calculations show that the steady-state abundance of p53 in the presence of HPV E6, $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$, is reduced to $1/\\gamma$ of its normal value, $P_{\\mathrm{ss}}$. With $\\gamma = 4.0$, this constitutes a $75\\%$ reduction in the cellular pool of p53. The protein p53 is a critical tumor suppressor, often termed the \"guardian of the genome,\" which functions, in part, by inducing apoptosis (programmed cell death) in response to cellular stress signals such as DNA damage.\n\nThe problem states that the propensity for apoptosis increases monotonically with the steady-state abundance of p53. Therefore, the drastic reduction of p53 levels from $P_{\\mathrm{ss}}$ to $P_{\\mathrm{ss}}^{(\\mathrm{E6})}$ significantly blunts the cell's ability to trigger apoptosis when its DNA is damaged. This impairment of the apoptotic checkpoint allows cells with potentially oncogenic mutations to survive, proliferate, and accumulate further genetic damage, thereby increasing the risk of malignant transformation. This molecular mechanism is a primary contributor to the oncogenicity of high-risk HPV types.", "answer": "$$ \\boxed{5.84 \\times 10^3} $$", "id": "2516291"}, {"introduction": "While disrupting cellular pathways like the p53 and Retinoblastoma (RB) networks is necessary for transformation, it may not be sufficient for a tumor to form and persist within a complete organism. The transformed cell must also contend with host immune surveillance, which can recognize and eliminate aberrant cells. This exercise simulates a xenograft experiment to quantitatively explore the concepts of oncogenic sufficiency and immune evasion [@problem_id:2516268]. By analyzing hypothetical tumor formation data in both immunocompetent and immunodeficient hosts, you will calculate a metric that helps distinguish the intrinsic tumor-forming potential of viral oncogenes from their ability to overcome host defenses.", "problem": "A research group investigates whether expression of specific viral oncogenes from high-risk human papillomavirus (HPV) is sufficient for tumorigenesis in vivo. They transform human keratinocytes with either the viral gene set *E7* alone or the combined set *E6* plus *E7*, where E6 degrades the tumor suppressor p53 protein and E7 inactivates retinoblastoma protein, thereby deregulating the cell cycle. To assess the role of host immune surveillance, they perform subcutaneous xenografts of the engineered cells into two host types: immunodeficient mice (for example, Non-Obese Diabetic/Severe Combined Immunodeficiency (NOD/SCID) mice) and immunocompetent syngeneic mice. The central dogma of molecular biology (DNA to RNA to protein) underlies the assumption that sustained expression of these viral genes yields stable oncoprotein production, and well-established observations in tumor immunology state that immunodeficient hosts lack effective T- and B-lymphocyte responses that would otherwise eliminate transformed cells.\n\nAssume that each injection into a mouse constitutes an independent Bernoulli trial with an unknown probability $p$ of forming a palpable tumor within a fixed observation window, so that $k$ tumors out of $n$ injections follows a binomial distribution. By maximizing the binomial likelihood with respect to $p$, one obtains a maximum likelihood estimate $\\hat{p}$ for each condition.\n\nIn a pilot dataset, the following outcomes were recorded:\n- E6 plus E7 in immunodeficient hosts: tumors in $18$ of $20$ injections.\n- E6 plus E7 in immunocompetent hosts: tumors in $12$ of $20$ injections.\n- E7 alone in immunodeficient hosts: tumors in $10$ of $20$ injections.\n- E7 alone in immunocompetent hosts: tumors in $2$ of $20$ injections.\n\nDefine the sufficiency retention metric\n$$S \\equiv \\frac{\\hat{p}_{\\mathrm{IC}}(\\mathrm{E6+E7})/\\hat{p}_{\\mathrm{ID}}(\\mathrm{E6+E7})}{\\hat{p}_{\\mathrm{IC}}(\\mathrm{E7})/\\hat{p}_{\\mathrm{ID}}(\\mathrm{E7})},$$\nwhere $\\hat{p}_{\\mathrm{IC}}$ and $\\hat{p}_{\\mathrm{ID}}$ denote the estimated take rates in immunocompetent and immunodeficient hosts, respectively. Intuitively, $S$ compares how well the combined viral gene set retains its take rate in the presence of an intact immune system relative to E7 alone, thereby relating immune evasion and cell-intrinsic sufficiency for tumorigenesis.\n\nCompute $S$ from the data above. Express your answer as a dimensionless decimal and round your answer to four significant figures.", "solution": "The problem asks for a quantitative comparison of xenograft take rates across host immune contexts and viral gene complements, grounded in two foundational elements:\n\n1. Central Dogma of Molecular Biology: Stable expression of viral genes (DNA encoding E6 and E7) leads to production of the corresponding oncoproteins, which can drive cellular transformation by functionally inactivating tumor suppressors (p53 and retinoblastoma protein).\n2. Binomial Model for Independent Trials: Each injection is modeled as an independent Bernoulli trial with probability $p$ of tumor formation. For $n$ injections and $k$ tumors observed, $k \\sim \\mathrm{Binomial}(n,p)$. The likelihood is $L(p) = \\binom{n}{k} p^{k} (1-p)^{n-k}$.\n\nTo estimate $p$, we maximize $L(p)$ (or equivalently the log-likelihood $\\ell(p) = \\ln L(p)$) with respect to $p$:\n$$\n\\ell(p) = \\ln \\binom{n}{k} + k \\ln p + (n-k) \\ln(1-p).\n$$\nDifferentiating and setting to zero,\n$$\n\\frac{d\\ell}{dp} = \\frac{k}{p} - \\frac{n-k}{1-p} = 0 \\quad \\Rightarrow \\quad k(1-p) = p(n-k) \\quad \\Rightarrow \\quad \\hat{p} = \\frac{k}{n}.\n$$\nThus, the maximum likelihood estimate of the take rate in each condition is simply the empirical proportion of tumors.\n\nCompute the estimates for each condition:\n\n- E6 plus E7, immunodeficient: $\\hat{p}_{\\mathrm{ID}}(\\mathrm{E6+E7}) = \\frac{18}{20} = 0.9$.\n- E6 plus E7, immunocompetent: $\\hat{p}_{\\mathrm{IC}}(\\mathrm{E6+E7}) = \\frac{12}{20} = 0.6$.\n- E7 alone, immunodeficient: $\\hat{p}_{\\mathrm{ID}}(\\mathrm{E7}) = \\frac{10}{20} = 0.5$.\n- E7 alone, immunocompetent: $\\hat{p}_{\\mathrm{IC}}(\\mathrm{E7}) = \\frac{2}{20} = 0.1$.\n\nNow compute the sufficiency retention metric $S$:\n$$\nS = \\frac{\\hat{p}_{\\mathrm{IC}}(\\mathrm{E6+E7})/\\hat{p}_{\\mathrm{ID}}(\\mathrm{E6+E7})}{\\hat{p}_{\\mathrm{IC}}(\\mathrm{E7})/\\hat{p}_{\\mathrm{ID}}(\\mathrm{E7})}\n= \\frac{0.6/0.9}{0.1/0.5}\n= \\frac{\\frac{2}{3}}{\\frac{1}{5}}\n= \\frac{2}{3} \\times 5\n= \\frac{10}{3}\n\\approx 3.333\\ldots\n$$\n\nRounding to four significant figures yields $3.333$.\n\nBiological interpretation (not required for the numerical answer): An $S$ substantially greater than $1$ indicates that the E6 plus E7 combination retains a larger fraction of its immunodeficient take rate when moved into an immunocompetent context compared to E7 alone, consistent with the notion that adding E6 confers additional cell-intrinsic sufficiency for tumorigenesis and/or reduces immune-mediated elimination relative to E7 alone. However, the requested deliverable is the computed value of $S$.", "answer": "$$\\boxed{3.333}$$", "id": "2516268"}, {"introduction": "After exploring the molecular and organismal levels of viral oncogenesis, the final step is to assess the impact on a public health scale. Epidemiological metrics are essential for understanding the population-level burden of a risk factor, such as infection with an oncogenic virus. This practice introduces the Population Attributable Fraction (PAF), a key measure that quantifies the proportion of disease cases in a population that can be ascribed to a specific exposure [@problem_id:2516234]. By deriving the PAF from first principles and applying it to realistic data for HPV and cervical cancer, you will connect the dots between the relative risk ($RR$) posed to an individual and the virus's overall impact on public health.", "problem": "Persistent infection with oncogenic types of Human Papillomavirus (HPV) can drive cellular transformation in the cervical epithelium, ultimately leading to invasive cervical cancer. Consider a closed female population ages $25$–$64$ years in which the point prevalence of persistent high-risk HPV infection is $p = 0.12$. A cohort study in the same population estimates the relative risk (RR) of developing cervical cancer for persistently infected women compared with uninfected women to be $\\mathrm{RR} = 30$. Using only the following foundational definitions and mixture reasoning, derive an analytic expression for the Population Attributable Fraction (PAF) due to persistent high-risk HPV infection, and then compute its value for the given $p$ and $\\mathrm{RR}$:\n- $p$ is the fraction of the population with the exposure (persistent high-risk HPV infection).\n- Relative risk (RR) is defined as $\\mathrm{RR} = I_{e}/I_{u}$, where $I_{e}$ is the disease incidence in the exposed group and $I_{u}$ is the disease incidence in the unexposed group.\n- Population Attributable Fraction (PAF) is the fractional reduction in the overall disease incidence that would occur if the exposure were eliminated while holding all else constant.\n\nYour derivation should begin from these definitions and the fact that overall incidence is the weighted average of exposed and unexposed incidences. After deriving the closed-form expression for PAF in terms of $p$ and $\\mathrm{RR}$, evaluate it numerically for $p = 0.12$ and $\\mathrm{RR} = 30$. Round your final numerical answer to $4$ significant figures. Express the PAF as a pure decimal fraction without a percent sign.", "solution": "The derivation proceeds from the foundational definitions provided.\n\nLet $I_{total}$ be the overall incidence of cervical cancer in the total population. This incidence is the weighted average of the incidence in the exposed group ($I_{e}$) and the incidence in the unexposed group ($I_{u}$). The weights are the proportions of the population in each group. The fraction of the population that is exposed is given by the prevalence, $p$. The fraction that is unexposed is therefore $1-p$.\n\nThe overall incidence is expressed as:\n$$I_{total} = (p \\cdot I_{e}) + ((1-p) \\cdot I_{u})$$\n\nThe definition of relative risk ($\\mathrm{RR}$) is given as $\\mathrm{RR} = \\frac{I_{e}}{I_{u}}$. We can rearrange this to express $I_{e}$ in terms of $I_{u}$ and $\\mathrm{RR}$:\n$$I_{e} = \\mathrm{RR} \\cdot I_{u}$$\n\nSubstitute this expression for $I_{e}$ into the equation for $I_{total}$:\n$$I_{total} = (p \\cdot (\\mathrm{RR} \\cdot I_{u})) + ((1-p) \\cdot I_{u})$$\n\nWe can factor out $I_{u}$:\n$$I_{total} = I_{u} \\cdot (p \\cdot \\mathrm{RR} + 1 - p)$$\n$$I_{total} = I_{u} \\cdot (1 + p(\\mathrm{RR} - 1))$$\n\nThe Population Attributable Fraction (PAF) is defined as the fractional reduction in overall incidence if the exposure were eliminated. If the exposure were eliminated from the population, the entire population would experience the incidence rate of the unexposed group, $I_{u}$. The new total incidence, $I_{new}$, would be $I_{u}$.\n\nThe reduction in incidence is the difference between the original total incidence and the new incidence:\n$$\\text{Reduction in Incidence} = I_{total} - I_{new} = I_{total} - I_{u}$$\n\nThe fractional reduction, which is the PAF, is this reduction divided by the original total incidence:\n$$\\mathrm{PAF} = \\frac{I_{total} - I_{u}}{I_{total}} = 1 - \\frac{I_{u}}{I_{total}}$$\n\nNow, we substitute our derived expression for $I_{total}$ into the formula for PAF:\n$$\\mathrm{PAF} = 1 - \\frac{I_{u}}{I_{u} \\cdot (1 + p(\\mathrm{RR} - 1))}$$\n\nThe term $I_{u}$ cancels from the numerator and the denominator, yielding the final analytical expression for PAF in terms of $p$ and $\\mathrm{RR}$:\n$$\\mathrm{PAF} = 1 - \\frac{1}{1 + p(\\mathrm{RR} - 1)}$$\n\nTo express this as a single fraction, we find a common denominator:\n$$\\mathrm{PAF} = \\frac{(1 + p(\\mathrm{RR} - 1)) - 1}{1 + p(\\mathrm{RR} - 1)}$$\n$$\\mathrm{PAF} = \\frac{p(\\mathrm{RR} - 1)}{1 + p(\\mathrm{RR} - 1)}$$\n\nThis is the required analytical expression.\n\nNow, we compute the numerical value using the given data: $p = 0.12$ and $\\mathrm{RR} = 30$.\n$$\\mathrm{PAF} = \\frac{0.12 \\cdot (30 - 1)}{1 + 0.12 \\cdot (30 - 1)}$$\n$$\\mathrm{PAF} = \\frac{0.12 \\cdot 29}{1 + 0.12 \\cdot 29}$$\n$$\\mathrm{PAF} = \\frac{3.48}{1 + 3.48}$$\n$$\\mathrm{PAF} = \\frac{3.48}{4.48}$$\n\nThe numerical value is:\n$$\\mathrm{PAF} \\approx 0.7767857...$$\n\nRounding to $4$ significant figures, as required, we obtain:\n$$\\mathrm{PAF} = 0.7768$$\nThis result signifies that approximately $77.68\\%$ of cervical cancer cases in this population are attributable to persistent high-risk HPV infection.", "answer": "$$\\boxed{0.7768}$$", "id": "2516234"}]}